Answers are grounded in this paper and cite their sources.
Retrospective study compares post-induction hypotension in elderly patients with metabolic diseases, suggesting higher risk with end-organ damage.
Objective: To compare the incidence of post-induction hypotension and the use of vasopressor drugs during induction among elderly patients who underwent general anesthesia, with and without underlying metabolic diseases and end-organ damage. Materials and Methods: A retrospective study was conducted on 1,390 elderly patients aged 65 years or older who underwent general anesthesia at Songklanagarind Hospital. The subjects were classified into three groups, Group R, elderly patients with no diabetes mellitus (DM), dyslipidemia (DLP), and hypertension (HTN), Group M, elderly patients with DM, HT, or DLP without end-organ damage, and Group E, elderly patients with DM, HT, or DLP with end-organ damage. Baseline characteristics were recorded according to patient factors, anesthetic factors, and surgical factors. The outcome was post-induction hypotension, defined as systolic blood pressure of less than 90 mmHg during the first 20 minutes after anesthesia induction. The information collected from the anesthetic records within the electronic hospital information system. Results: Among the present study patients, 22.7% were in Group R, 49.5% were in Group M, and 27.8% were in Group E. The incidence of postinduction hypotension in Groups R, M, and E was 27.9%, 28.3%, and 35.1%, respectively with R versus M at adjusted OR 1.05, 95% CI 0.78 to 1.43, and R versus E at adjusted OR 1.49, 95% CI 1.06 to 2.08. The incidence of vasopressor drug usage during induction in Groups R, M, and E was 27.6%, 29.5%, and 38.0%, respectively with R versus M at adjusted OR 1.10, 95% CI 0.82 to 1.49 and R versus E at adjusted OR 1.58, 95% CI 1.14 to 2.21. Conclusion: The incidences of post-induction hypotension and the use of vasopressor drugs during induction were higher in elderly patients with metabolic diseases and end-organ damage compared to those without metabolic diseases.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: